Physician profile
Anthony Azar
NPI 1457307506
$2,390.02
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $238 · 2021: $286 · 2022: $376 · 2023: $556 · 2024: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $444.46 | 2022-2023 | Xeomin |
| Gilead Sciences, INC. | $407.51 | 2019-2024 | Descovy |
| Medtronic Vascular, INC. | $239.09 | 2019 | |
| Abbvie INC. | $210.78 | 2021-2023 | Vraylar |
| Pfizer INC. | $168.38 | 2024 | |
| Allergan, INC. | $165.32 | 2020 | |
| Amgen INC. | $153.71 | 2019-2024 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $141.31 | 2019-2024 | Breztri |
| Glaxosmithkline, LLC. | $102.64 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $78.03 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $57.49 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $47.26 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.18 | 2024 | Trulance, Xifaxan |
| Abbott Laboratories | $26.67 | 2022 | |
| Azurity Pharmaceuticals, INC. | $24.76 | 2023 | Adthyza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.67 | 2020 | |
| Galderma Laboratories, L.P. | $15.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.